Not all skinny: The French do get fat

The announcement that France will now reimburse prescription anti-obesity drugs like Wegovy and Mounjaro marks more than a shift in healthcare policy—it reflects a quiet but undeniable reckoning with a health crisis that has quietly reshaped French society over the past three decades. France, long mythologized for its slender stereotypes, has seen obesity rates triple since the 1990s, with nearly one in two adults now classified as overweight or obese. This trend mirrors broader patterns across Europe, where economic transitions, dietary shifts, and sedentary lifestyles have eroded traditional models of health. The reimbursement policy, however, signals a pragmatic admission that prevention alone has failed, and that medical intervention is now a necessary tool in a nation where food remains a cultural cornerstone. The conditions for reimbursement reveal as much as they conceal. Patients must meet strict BMI thresholds, typically BMI ≥ 30 or ≥ 27 with obesity-related comorbidities, and demonstrate prior attempts at diet and lifestyle changes—requirements that prioritize clinical oversight but risk excluding those who need help most. France’s approach contrasts sharply with the United States, where these drugs have been more widely adopted but often at prohibitive costs, highlighting a European emphasis on equitable access. Still, questions linger about long-term sustainability. Anti-obesity medications are not a cure but a management tool, often requiring lifelong use, and their inclusion in public health coverage could strain an already stretched healthcare budget. What happens next will hinge on two fronts: uptake and adaptation. Will French doctors prescribe these drugs at scale, or will cultural stigma around medication blunt their impact? Will France invest in parallel strategies, like expanding nutrition education or urban design to encourage movement? The move also raises broader questions about how societies reconcile economic pressures with cultural identity. As France navigates this balance, its choices could offer lessons for other nations grappling with obesity as both a health and social challenge. The story is no longer about whether France can stay thin—it’s about whether it can stay healthy.